Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Much Is the Global Antiemetics And Antinauseants Market Valued at Present and by 2029?
The peptide-based metabolic disorder treatments market has seen a steep increase in its size over the past few years. The market expansion is projected to continue from $29.89 billion in 2024 to $34.1 billion in 2025, growing at a compound annual growth rate (CAGR) of 14.1%. Factors such as the growing cases of metabolic disorders, advancements in peptide synthesis technology, increased healthcare spending, an aging population, a flourishing biopharmaceutical industry, approval of new treatments, and a heightened understanding of personalized medicine, have all contributed to the growth experienced in the past.
The therapeutics market for peptide-based metabolic disorders is anticipated to experience substantial growth in the coming years, escalating to “$57.13 billion in 2029 with a compound annual growth rate (CAGR) of 13.8%. Several reasons can be cited for this development during the forecast period, including the creation of new peptide analogs, increased R&D funding for metabolic disorders, the use of precision medicine, the proliferation of emerging markets, partnerships and collaborative efforts in drug development, advancements in delivery technologies, and a focus on patient-centered therapies. Key trends during this period are expected to feature artificial intelligence applications in drug discovery, the surge in personalized therapies, the use of CRISPR/Cas9 for genetic therapies, wearable devices integration for patient monitoring, the introduction of oral peptide formulations, the increase of digital therapeutics in disease control, and the extension of biobanking for customized treatments.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16764&type=smp
#What Drivers Are Influencing Growth In The Antiemetics And Antinauseants Market?
The market for antiemetics and antinauseants is influenced by the escalating prevalence of cancer. One of the most advised remedies for cancer is chemotherapy, which unfortunately leads to side effects such as chemotherapy-induced nausea and vomiting (CINV). Fortunately, antiemetics have been found to prevent CINV in about 60%-70% of patients. For example, The American Cancer Society, a U.S.-based non-profit organization, estimated in April 2024 that around 609,000 cancer-related deaths occurred and approximately 1.9 million new cancer cases were detected in the country in the year 2022. They projected about 620,000 deaths due to cancer, indicating a slight surge in mortality rates in 2024. This growing occurrence of cancer will boost the need for antiemetics and antinauseants, thereby stimulating market revenue.
The peptide based metabolic disorders therapeutics market covered in this report is segmented –
1) By Drug Type: Liraglutide, Exenatide, Other Drug Type
2) By Application: Lysosomal Storage Diseases, Diabetes, Obesity, Hypercholesterolemia, Other Applications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Liraglutide: Brand: Saxenda, Brand: Victoza, Generic Liraglutide, Liraglutide For Type 2 Diabetes, Liraglutide For Obesity
2) By Exenatide: Brand: Byetta, Brand: Bydureon, Exenatide For Type 2 Diabetes, Extended-Release Exenatide, Generic Exenatide
3) By Other Drug Type: Semaglutide, Dulaglutide, Albiglutide, Lixisenatide, GLP-1 Receptor Agonists, Pramlintide, Other Peptide-Based Drugs For Metabolic Disorders
What Are The Leading Trends And Opportunities In The Antiemetics And Antinauseants Sector?
Leading enterprises in the peptide-based metabolic disorder therapeutics market are pioneering the creation of novel peptide-centered treatments, including anti-diabetic biosimilars, with an aim to fill existing medical gaps and diversify available treatment options for patients. Anti-diabetic biosimilars, grounded in peptides, are therapeutic drugs designed to emulate existing peptide-anchored therapies for diabetes, furnishing parallel efficacy and safety metrics to those of established drugs, whilst possibly reducing treatment expenses via competitive pricing mechanisms. For example, in January 2024, Glenmark Pharmaceuticals Ltd, a pharmaceutical firm based in India, introduced Lirafit, an analogue of the frequently-prescribed anti-diabetic medication, Liraglutide, in the Indian market. This drug forms part of the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) drug class. This specific category of drugs copies the function of the natural GLP-1 hormone, integral in managing sugar levels in the bloodstream. Clinical trials have shown this biosimilar to be effective in minimizing glycemic indicators, facilitating weight loss, and improving cardiovascular safety. These benefits are vital in controlling diabetes and related conditions such as obesity and cardiovascular diseases.
Which Companies Play A Key Role In The Development Of The Antiemetics And Antinauseants Market?
Major companies operating in the peptide based metabolic disorders therapeutics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, Merck And Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Eli Lilly Company, Amgen Inc., Gilead Sciences Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Jazz Pharmaceuticals plc, Ipsen S.A, BioMarin Pharmaceutical Inc., Amarin Corporation plc, PolyPeptide Group
What Are The Key Regional Developments Shaping The Antiemetics And Antinauseants Market?
North America was the largest region in the peptide based metabolic disorders therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide based metabolic disorders therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=16764&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
